Zacks Research Issues Negative Outlook for Sanofi Earnings

Sanofi (NASDAQ:SNY) – Investment analysts at Zacks Research dropped their Q3 2025 earnings estimates for shares of Sanofi in a report released on Wednesday, March 5th. Zacks Research analyst K. Shah now anticipates that the company will earn $1.57 per share for the quarter, down from their prior forecast of $1.59. The consensus estimate for Sanofi’s current full-year earnings is $4.36 per share. Zacks Research also issued estimates for Sanofi’s Q2 2026 earnings at $1.00 EPS and FY2027 earnings at $4.75 EPS.

SNY has been the subject of a number of other reports. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Finally, StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $60.00.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $58.74 on Monday. Sanofi has a twelve month low of $45.22 and a twelve month high of $60.12. The stock has a market capitalization of $149.07 billion, a PE ratio of 23.59, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. The firm’s 50 day moving average price is $53.08 and its 200-day moving average price is $52.78. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Farther Finance Advisors LLC raised its position in Sanofi by 12.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 2,861 shares of the company’s stock valued at $165,000 after purchasing an additional 309 shares in the last quarter. Verdence Capital Advisors LLC grew its stake in shares of Sanofi by 2.6% in the 3rd quarter. Verdence Capital Advisors LLC now owns 30,523 shares of the company’s stock valued at $1,759,000 after purchasing an additional 764 shares during the last quarter. Assetmark Inc. grew its stake in shares of Sanofi by 9.8% in the 3rd quarter. Assetmark Inc. now owns 109,375 shares of the company’s stock valued at $6,303,000 after purchasing an additional 9,787 shares during the last quarter. Atria Investments Inc boosted its stake in shares of Sanofi by 0.7% in the third quarter. Atria Investments Inc now owns 107,296 shares of the company’s stock valued at $6,183,000 after buying an additional 701 shares in the last quarter. Finally, Legacy Capital Wealth Partners LLC raised its holdings in Sanofi by 114.2% during the third quarter. Legacy Capital Wealth Partners LLC now owns 24,274 shares of the company’s stock worth $1,399,000 after purchasing an additional 12,942 shares during the last quarter. 14.04% of the stock is owned by institutional investors and hedge funds.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.